These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22809538)

  • 41. Predictors of death and occurrence of appropriate implantable defibrillator therapies in patients with ischemic cardiomyopathy.
    Ng AC; Bertini M; Borleffs CJ; Delgado V; Boersma E; Piers SR; Thijssen J; Nucifora G; Shanks M; Ewe SH; Biffi M; van de Veire NR; Leung DY; Schalij MJ; Bax JJ
    Am J Cardiol; 2010 Dec; 106(11):1566-73. PubMed ID: 21094356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database.
    MacFadden DR; Crystal E; Krahn AD; Mangat I; Healey JS; Dorian P; Birnie D; Simpson CS; Khaykin Y; Pinter A; Nanthakumar K; Calzavara AJ; Austin PC; Tu JV; Lee DS
    Ann Intern Med; 2012 Feb; 156(3):195-203. PubMed ID: 22312139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of accelerated ventricular tachyarrhythmias on mortality in patients with implantable cardioverter-defibrillator therapy.
    Schukro C; Leitner L; Siebermair J; Pezawas T; Stix G; Kastner J; Schmidinger H
    Int J Cardiol; 2013 Sep; 167(6):3006-10. PubMed ID: 23017814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implantable cardioverter-defibrillator patients who are upgraded and respond to cardiac resynchronization therapy have less ventricular arrhythmias compared with nonresponders.
    Thijssen J; Borleffs CJ; Delgado V; van Rees JB; Mooyaart EA; van Bommel RJ; van Erven L; Boersma E; Bax JJ; Schalij MJ
    J Am Coll Cardiol; 2011 Nov; 58(22):2282-9. PubMed ID: 22093504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
    Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
    Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction.
    Naksuk N; Saab A; Li JM; Florea V; Akkaya M; Anand IS; Benditt DG; Adabag S
    J Card Fail; 2013 Jun; 19(6):426-30. PubMed ID: 23743493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers.
    Hreybe H; Bedi M; Ezzeddine R; Barrington W; Jain S; Ngwu O; Saba S
    Am Heart J; 2005 Nov; 150(5):1064. PubMed ID: 16290997
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emotional distress, positive affect, and mortality in patients with an implantable cardioverter defibrillator.
    van den Broek KC; Tekle FB; Habibović M; Alings M; van der Voort PH; Denollet J
    Int J Cardiol; 2013 May; 165(2):327-32. PubMed ID: 21963213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy.
    Williams ES; Shah SH; Piccini JP; Sun AY; Koontz JI; Al-Khatib SM; Hranitzky PM
    Europace; 2011 Dec; 13(12):1717-22. PubMed ID: 21821855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter-defibrillators.
    Swerdlow CD; Ahern T; Kass RM; Davie S; Mandel WJ; Chen PS
    J Am Coll Cardiol; 1996 Apr; 27(5):1112-8. PubMed ID: 8609329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased anxiety in partners of patients with a cardioverter-defibrillator: the role of indication for ICD therapy, shocks, and personality.
    Pedersen SS; VAN DEN Berg M; Erdman RA; VAN Son J; Jordaens L; Theuns DA
    Pacing Clin Electrophysiol; 2009 Feb; 32(2):184-92. PubMed ID: 19170907
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias.
    Ypenburg C; van Erven L; Bleeker GB; Bax JJ; Bootsma M; Wijffels MC; van der Wall EE; Schalij MJ
    J Am Coll Cardiol; 2006 Aug; 48(3):464-70. PubMed ID: 16875970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience.
    Aydin A; Hartel F; Schlüter M; Butter C; Köbe J; Seifert M; Gosau N; Hoffmann B; Hoffmann M; Vettorazzi E; Wilke I; Wegscheider K; Reichenspurner H; Eckardt L; Steven D; Willems S
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):913-9. PubMed ID: 22923274
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications.
    van der Heijden AC; Borleffs CJ; Buiten MS; Thijssen J; van Rees JB; Cannegieter SC; Schalij MJ; van Erven L
    Heart Rhythm; 2015 Jun; 12(6):1169-76. PubMed ID: 25749138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of digoxin on shocks in cardiac resynchronization therapy-defibrillator patients with coronary artery disease.
    Adelstein E; Schwartzman D; Jain S; Bazaz R; Saba S
    Am J Cardiol; 2014 Mar; 113(6):970-5. PubMed ID: 24440327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-implantation psychological functioning preserved in majority of implantable cardioverter defibrillator patients 12 months post implantation.
    Pedersen SS; Hoogwegt MT; Jordaens L; Theuns DA
    Int J Cardiol; 2013 Jun; 166(1):215-20. PubMed ID: 22071036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The distressed (Type D) personality in both patients and partners enhances the risk of emotional distress in patients with an implantable cardioverter defibrillator.
    van den Broek KC; Versteeg H; Erdman RA; Pedersen SS
    J Affect Disord; 2011 May; 130(3):447-53. PubMed ID: 21093061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.